Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

IBM & Japan’s Rapidus Aiming to Manufacture The World’s Most Advanced Chips – $IBM $DIA $INVO

By John F. Heerdink, Jr.

As per reports, International Business Machines Corporation (IBM) partnered with a newly formed chip maker, Rapidus, backed by the Japanese government aimed to manufacture the world’s most advanced chips in Japan by the second half of the decade. Japan’s industry and trade ministry has agreed to invest an initial 70 billion yen in Rapidus, a venture by tech firms including Sony Group Corp and NEC Corp. The agreement comes amid tense U.S.-China relations, and has restricted Beijing’s access to advanced semiconductor technology, and has asked its allies, including Japan, to implement the same. 

“It will take several trillions of yen,” to get pilot production up and running, stated Rapidus president Atsuyoshi Koike, not informing from where the money would come for.

Dario Gil, IBM’s director of research informed that the two companies will collaborate to manufacture IBM’s 2-nanometer-node chips, unveiled last year, and Rapidus scientists and engineers will work alongside IBM Japan and IBM researchers at the Albany NanoTech Complex in New York state.

Dow 30 component International Business Machines Corporation (IBM) provides information technology (IT) products and services worldwide. Please visit the Vista Partners IBM Coverage Page to learn more about International Business Machines Corp (IBM) and track its ongoing progress. 

Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.


Japan is one of the few super-aged societies worldwide and has faced a prolonged fertility decline for decades. Following the end of World War II, the nation experienced swift economic growth, vast improvements in the health care system, and a subsequent baby boom (1947-1949). After the second baby boom (1971-1974), however, Japan saw a downturn in the fertility rate, defined as the number of children born per woman of childbearing age. This downward trend was mainly attributed to the economic recession from the 1973 oil crisis and the social shifts aiming for a stationary population. The rate continued to decline in the 1980s and the 1990s, partially due to an accelerated female employment rate and rising average marital age after the enactment of the Equal Employment Opportunity Law in 1985. In 2005, the fertility rate marked the lowest rate in history at 1.26 and increased concerns for the country’s demographics. The rate slightly recovered over the following years and was 1.34 in 2020. 

From April 2022, all basic infertility treatments, such as timing therapy and artificial insemination, as well as ART procedures like IVF, micro-fertilization, and embryo freezing for women aged 42 years or younger, are covered by health insurance.

If you have ever struggled with infertility issues, or know someone who has, you are probably well aware of how demoralizing it can be. Imagine for a moment spending thousands of dollars and months of intensive medical procedure only to end up empty handed, exhausted, sad, and defeated because after all of that time, work, and money, you still don’t have a baby. That’s an incredibly difficult situation, and it’s becoming more common each passing year. Likewise, the need for more effective, less invasive infertility treatment options is increasing with each passing year. This is the sole focus of medtech company INVO Bioscience (NASDAQ: INVO). Learn more by reading the following story that we published recently. 

INVO Bioscience (NASDAQ: $INVO), A Company Seeking To Address A Massively Underserved Fertility Market

(Read Original Story: UPDATE 1-IBM partners with Japan's Rapidus in bid to manufacture advanced chips in IBM has)


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us